CYP19A1 and cancer: Aromatase inhibitors inhibit the aromatase enzyme, which turns androgens into estrogen. This reduction in estrogen effectively hinders the growth signal for ER+ cancer cells, leading to improved clinical trial outcomes and lower recurrence rates.